Giredestrant vs Palazestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Giredestrant
Marketed by Roche
NCT04546009 · Phase 3 · active, not recruiting
This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.
Next expected readout: July 2027 · NCT03332797 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)
Result source: NCT04546009
Palazestrant
Developed by Olema Pharmaceuticals, Inc.
NCT04505826 · Phase 1/2 · completed
The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.
Next expected readout: December 2027 · NCT05508906 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Giredestrant | Palazestrant |
|---|---|---|
| PFS, median | —Trial running · NCT06065748 | —Trial running · NCT06016738 |
| OS, median | —Trial running · NCT06065748 | —Trial running · NCT06016738 |
| ORR | —Trial running · NCT06065748 | —Trial running · NCT06016738 |
| Clinical benefit rate | —Trial running · NCT06065748 | —Trial running · NCT06016738 |
PFS, median
- Giredestrant
- —Trial running · NCT06065748
- Palazestrant
- —Trial running · NCT06016738
OS, median
- Giredestrant
- —Trial running · NCT06065748
- Palazestrant
- —Trial running · NCT06016738
ORR
- Giredestrant
- —Trial running · NCT06065748
- Palazestrant
- —Trial running · NCT06016738
Clinical benefit rate
- Giredestrant
- —Trial running · NCT06065748
- Palazestrant
- —Trial running · NCT06016738
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Giredestrant: 3 of 4 rows · Palazestrant: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Giredestrant | Palazestrant |
|---|---|---|
| Dropout rate | 8.7%a NCT05659563 · Phase 2 · registry result, not featured evidence | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results0%300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 0%210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 0%150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 0%120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 0%90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 |
| Discontinued due to AEs | —a NCT05659563 · Phase 2 · registry result, not featured evidence | —300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 |
| Serious AEs | 0%a NCT05659563 · Phase 2 · registry result, not featured evidence | 28.6%300 mg QDa NCT04505826 · Phase 1/2 show 14 more results—300 mg QD NCT04505826 · Phase 1/2 28.6%210 mg QD NCT04505826 · Phase 1/2 —210 mg QD NCT04505826 · Phase 1/2 40%150 mg QD NCT04505826 · Phase 1/2 —150 mg QD NCT04505826 · Phase 1/2 19.3%120 mg QD NCT04505826 · Phase 1/2 57.1%120 mg QD NCT04505826 · Phase 1/2 —120 mg QD NCT04505826 · Phase 1/2 33.3%90 mg QD NCT04505826 · Phase 1/2 —90 mg QD NCT04505826 · Phase 1/2 12.1%60 mg QD NCT04505826 · Phase 1/2 —60 mg QD NCT04505826 · Phase 1/2 0%30 mg QD NCT04505826 · Phase 1/2 —30 mg QD NCT04505826 · Phase 1/2 |
| Most frequent reported AEs | a arthralgia 9.5% hot flush 9.5% fatigue 7.1% NCT05659563 · Phase 2 · registry result, not featured evidence | show 7 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Giredestrant
Palazestrant
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Palazestrant's landscape